Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment that uses targeted magnetic pulses to stimulate underactive brain regions, most commonly used for depression and OCD in patients who haven't responded adequately to medication.

A magnetic coil positioned against the scalp delivers rapid pulses that cause neurons in the targeted region to fire, with repeated sessions gradually strengthening those circuits through the brain's natural capacity for neuroplasticity.

No. TMS is FDA-cleared, backed by decades of clinical research, and has been the subject of thousands of peer-reviewed studies, including a consensus statement from seventeen clinical experts who reviewed approximately 1,500 publications confirming its safety and efficacy for major depressive disorder (McClintock et al., 2018).

For major depressive disorder, response rates in clinical trials typically fall between 50 and 60 percent, meaningfully significant given that most TMS patients have already failed to respond to medication. Results vary by individual and condition, and outcomes are strongest when TMS is combined with supportive lifestyle habits.

Is TMS covered by insurance?

Most major US insurers cover TMS for treatment-resistant depression, but coverage for other conditions varies and typically requires prior authorization and documentation of failed medication trials.

How much does TMS cost?

A full course of TMS ranges from roughly $6,000 to $12,000 out of pocket, though insured patients may pay significantly less; it's worth contacting both the clinic and insurer directly to understand what's covered before committing.

Does TMS help with anxiety?

Often, though mostly by an indirect route. TMS's established clearances are for depression, OCD, and smoking cessation, and many people treated for depression find their anxiety eases as the same prefrontal circuits regain healthy activity. Research on TMS for standalone anxiety disorders is younger and less settled, so ask what protocol a clinic would use and what evidence backs it.

How long does TMS take to work?

TMS is a course of treatment, not a single procedure: standard protocols involve brief daily sessions five days a week over several weeks. People who respond typically start noticing changes partway through, often a few weeks in, with mood, sleep, or energy shifting first. Clinicians generally advise finishing the full protocol before judging whether it worked.

How long do the results of TMS last?

Pooled follow-up gives a more sober figure than the two years sometimes quoted: among people who respond, roughly half still hold their gains at twelve months, and relapse during the first year is common. Booster sessions recover the response for most people who lose it, which is why maintenance is built into many programs. Durability also depends on what you do after: patients who pair TMS with exercise, sleep, social connection, and stress management hold gains longest.

What are the side effects of TMS?

The common ones are local and temporary: scalp discomfort, mild headache, and sometimes fatigue after early sessions, all of which tend to fade within the first week or two. TMS does not cause the memory loss associated with ECT, and a major expert consensus reviewing roughly 1,500 studies concluded rTMS is safe and effective for major depression. The one serious risk, seizure, is rare and screened for; clinics ask about seizure history and metal implants.

Most people describe it as a firm tapping or woodpecker-like knocking on the scalp rather than pain. The discomfort usually eases within a week, and technicians can adjust the coil position or intensity if it does not. There is no anesthesia and no sedation; you are awake throughout and can drive yourself home.

Who is a good candidate for TMS?

The classic candidate has depression that has not responded to one or more antidepressants, or cannot tolerate medication side effects like weight gain, sexual dysfunction, or cognitive dulling. Response rates for treatment-resistant depression run 30 to 64 percent, and TMS is also cleared for OCD and smoking cessation. It is not suitable for people with certain metal implants in or near the head or with significant seizure risk.

Is TMS the same as shock therapy (ECT)?

No. ECT deliberately induces a seizure under general anesthesia and can affect memory, while TMS uses targeted magnetic pulses to stimulate a specific brain region, with no anesthesia and no memory loss. ECT is generally reserved for the most severe, urgent cases, while TMS is an outpatient option people fit around work and daily life.

Transcranial Magnetic Stimulation (TMS)

How transcranial magnetic stimulation (TMS) works

TMS is a brain stimulation therapy that doesn't require surgery, anesthesia, or electricity passed through the skull. It uses precisely targeted magnetic pulses to activate specific areas of the brain, stimulating neurons (brain cells) to fire.

TMS positions a magnetic coil over the DLPFC (a brain region that regulates mood) to generate a brief electrical current in surrounding tissue, depolarizing local neurons and triggering them to fire. In rTMS, pulses are delivered in rapid sequences. High-frequency stimulation (5 Hz or above) is excitatory, while lower frequencies (around 1 Hz) are inhibitory, and personalized protocols need to be developed (Cao et al., 2018).

What conditions is it used for

Treatment-resistant depression (TRD)
Obsessive-compulsive disorder (OCD)
Anxious depression
Smoking cessation
Post-traumatic stress disorder (PTSD)
Attention-deficit hyperactivity disorder (ADHD)
Parkinson's disease
Chronic pain
Traumatic brain injury (TBI) recovery

What to expect during treatment

TMS sessions are outpatient, so you drive yourself, there's no recovery period, and normal activity resumes immediately. Sessions run between 20 and 40 minutes, with a standard course of five sessions per week for four to six weeks, totaling around 30 sessions.

Prior to treatment, a clinician conducts a comprehensive evaluation and calibration to determine the appropriate stimulation intensity. During sessions, a coil placed against the scalp produces a rapid clicking or tapping sensation that some find uncomfortable initially but typically adjust to.

Most people notice improvements in mood, sleep, or motivation after the first few weeks.

Insurance coverage varies considerably, so checking with your provider early is worthwhile.

The mechanism in depth

Transcranial magnetic stimulation (TMS) sounds like something out of a sci-fi movie, but it's actually a clinical tool for certain types of depression and other mental health conditions.

TMS has been around for several decades, with the first demonstration in 1985 by British neurologist Anthony Barker, who showed that a magnetic coil held to the scalp could make a person's hand move, proving the brain could be stimulated externally and non-invasively.

The FDA cleared repetitive TMS (rTMS) for treatment-resistant depression in 2008, and additional clearances have been added since, setting it up to be a more widely utilized clinical tool in several areas of mental health.

In conditions like depression and PTSD, specific brain regions lose their healthy communication patterns with the rest of the brain, which has numerous impacts on behavior, mood, and emotional regulation. TMS is meant to help things return to working together harmoniously again.

In depression, the most relevant region is the dorsolateral prefrontal cortex (DLPFC), located toward the front and side of the brain. The DLPFC is key to mood regulation, executive function, and emotional responses, and is characteristically underactive in depression, which is why it's targeted with TMS.

The benefit of TMS appears to depend on neuroplasticity, which is the brain's capacity to adapt in response to experiences. With enough repetition, stimulated circuits strengthen and form more reliable connections.

Researchers believe TMS also influences neurotransmitter activity (dopamine, serotonin, and glutamate levels appear to change following treatment), but the exact mechanisms aren't yet fully understood. TMS works well enough to have earned FDA clearance and a large evidence base, but neuroscientists don't know the whole story.

The first clinical use for TMS was treatment-resistant depression (TRD), and the majority of those who seek it out tend to fit this category. These are people who have been through many drug trials, including various combinations, without adequate depression relief. TRD can be very frustrating with all of the trial and error in treatment.

Roughly one in three people with major depression doesn't achieve remission with their first antidepressant, and many don't with their second or third. TMS offers an intervention at the level of brain circuitry versus the neurochemistry approach of standard antidepressants.

Furthermore, it's helpful to understand what TMS doesn't claim to do: resolve underlying sources of stress, trauma, or lifestyle factors contributing to mental health conditions. TMS works best when patients are also optimizing sleep, exercise, social connection, and stress management, taking into account their broader lifestyle habits.

Common uses

In addition to treatment-resistant depression, the FDA has cleared TMS for OCD, anxious depression, and smoking cessation. There is also a growing body of evidence for its use in post-traumatic stress disorder (PTSD), attention-deficit hyperactivity disorder (ADHD), Parkinson's disease, chronic pain, and recovery following traumatic brain injury (TBI).

Some of these are heading toward becoming established applications; others are still experimental, though TMS can still be prescribed off-label by clinicians as deemed appropriate.

What the evidence supports

The strongest evidence for TMS is with MDD.

Major depressive disorder (MDD)

Major depressive disorder (MDD) is characterized by persistent low mood, loss of interest or pleasure, trouble sleeping, fatigue, and difficulty concentrating, which significantly impact daily function and quality of life.

A consensus statement authored by seventeen clinical experts reviewed approximately 1,500 studies and 118 key publications, concluding that rTMS is both safe and effective for MDD, including in patients who had not responded to antidepressant medication (McClintock et al., 2018).

Response rates typically fall between 50 and 60 percent, with remission in roughly a third, clinically significant given that these are largely patients for whom medication has already failed. Effects typically persist for around two years, with some patients maintaining benefits longer.

Obsessive compulsive disorder

In OCD, the brain's cortico-striato-thalamo-cortical (CSTC) circuit (a loop connecting the parts of the brain that regulate the filtering of repetitive thoughts and urges) becomes overactive and stuck, failing to send the “good enough” signal that tells the brain a thought or action can stop.

This hyperactivity is what encourages the intrusive thoughts and compulsive behaviors characteristic of OCD. Using TMS to target the medial prefrontal cortex aims to help this overactive circuitry return to normal function.

A multicenter randomized controlled trial of 99 patients found that deep TMS targeting the medial prefrontal cortex produced a 38.1% response rate compared to 11.1% in the sham group, with effects maintained at one month (Carmi et al., 2019).

A network meta-analysis confirmed that all major rTMS protocols produced significant clinical improvements for OCD compared to sham stimulation (Steuber et al., 2023). FDA clearance for OCD followed in 2018.

Where the evidence is limited

Beyond depression and OCD, the evidence is thinner and less consistent.

Post-traumatic stress disorder (PTSD)

PTSD can develop after exposure to traumatic events, characterized by intrusive memories, hypervigilance, and avoidance behaviors driven by a dysregulation in the brain's fear circuitry.

While there's interest in understanding potential uses for TMS in PTSD, trials have generally been smaller, less consistent in protocol, and more variable in outcomes than the depression literature (Edinoff et al., 2022).

The rationale is sound, as the prefrontal cortex loses its ability to modulate the overactive fear response driven by the amygdala, the same circuitry TMS addresses in depression. But the evidence base isn't yet comparable.

Other potential uses

ADHD, chronic pain, Parkinson's disease, and TBI-related cognitive recovery are active research areas, but studies frequently involve small samples, lack rigorous sham controls, or haven't been replicated at scale.

Clinicians also still cannot reliably identify in advance which patients will respond to TMS and which won't.

Safety and regulations

TMS has a reassuring safety profile backed by decades of use. In the United States, TMS devices are FDA-cleared (not the same as FDA-approved) for MDD, OCD, anxious depression, and smoking cessation.

Off-label use for PTSD, ADHD, and others is legal but relies on clinical judgment. TMS is also cleared across most of Europe, Canada, Australia, and Israel, though specific details differ by country.

Unlike electroconvulsive therapy (ECT), TMS doesn't pose a risk of memory impairment, and unlike medications, it produces no weight changes, sexual dysfunction, or withdrawal effects. Side effects are typically mild and self-resolving, like:

Headache or scalp discomfort during early sessions
Neck stiffness or facial twitching during stimulation
Seizure risk, which is very small and estimated to be around 1 seizure per 30,000 sessions (Taylor et al., 2021)

Contraindications include ferromagnetic implants in or near the head, certain implanted cardiac devices, active seizure disorders, and heavy substance use. Pregnancy is evaluated case by case, and TMS is currently cleared for adults only, though evidence in younger populations is developing.

The future of TMS

TMS is becoming more accessible. Theta burst stimulation, which is already used clinically, turns a full therapeutic session into as little as three minutes. This matters because the traditional barrier to TMS wasn't just cost or clinical availability, it was time.

There's also a shift toward more personalization in treatments. Emerging neuroimaging research maps individual brain connectivity to identify the optimal stimulation site for each person.

PTSD trials are advancing (such as clinical trials on TMS for veterans and first responders), accelerated multi-session-per-day protocols show early promise, and longer-horizon research is underway in Alzheimer's disease, cognitive decline, and substance use disorders (Atoui et al, 2025).

Overall, TMS appears to be becoming more integrated and personalized as one component of a coordinated approach to recovery.

Takeaway

TMS is a well-evidenced, non-invasive treatment for various mental health conditions that offers genuine relief to people for whom conventional options have fallen short, and its applications are expanding.

As with any treatment, TMS works best for patients who treat it as one part of a broader commitment to their health.

If you’re looking for a provider, you can browse vetted TMS clinics across the U.S. in our directory.